Autologous stem cell transplantation is standard therapy for mantle cell lymphoma.
We hypothesize that minimal residual disease could stratify outcomes for transplantation.
Minimal residual disease positivity was associated with shorter overall survival and progression-free survival.
Minimal residual disease positivity is independently associated with poor outcome after transplantation.